
Gregory J. Riely, MD, PhD
Thoracic Oncologist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Request an Appointment
About Me
- Vice Chair of Clinical Research, Department of Medicine
I am a board-certified medical oncologist who specializes in treating patients with lung cancer and thymic tumors (thymoma and thymic carcinoma).
In addition to caring for men and women with these diseases, I work to develop new treatments by designing and conducting clinical trials. My clinical research focuses on the treatment of patients with thymic tumors as well as non-small cell lung cancer with specific mutations (EGFR, KRAS, BRAF, or EML4-ALK mutant non-small cell lung cancer).
A thoracic oncologist is a cancer doctor with special training in thoracic (thor-A-sik) cancers. These are cancers that have to do with the chest, including lung, tracheal (windpipe), and thymic (thymus) cancers.
My Specialties
- Thoracic Oncology
- Lung Cancer
- Thymoma
- Thymic Carcinoma
Education
- MD, Case Western Reserve University
Residencies
- Internal Medicine - New York Presbyterian/Weill Cornell Medical Center
Awards and Honors
- Top Doctors New York Metro Area, Castle Connolly (2023)
- Fellow, American Society of Clinical Oncology (2023)
- Castle Connolly: America's Top Doctors (2023)
- Castle Connolly: New York Magazine: Top Doctor (2018-2019, 2021)
Fellowships
- Medical Oncology - Memorial Sloan Kettering Cancer Center
- Medicine - Weill Cornell Medical College
Board Certifications
- Internal Medicine
- Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment

New Patients
Current Patients
Contact and Location
Dr. Riely sees patients at two locations.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Riely
- A Phase 1/2 Study of Lorlatinib Plus Ramucirumab in People With Advanced Lung Cancer
- Clinical Trials Co-Investigated by Dr. Riely
- A Phase 1 Study of AZD9592 Alone and With Other Treatments in People With Solid Tumors
- A Phase 1 Study of RMC-6291 in People with KRAS-Mutated Solid Tumors
- A Phase 1/2 Study of VS-6766 plus Adagrasib for People with Non-Small Cell Lung Cancer
Read more
- A Phase I Study of BDTX-1535 in People with Advanced Non-Small Cell Lung Cancer
- A Phase I Study of Patritumab Deruxtecan in Combination with Osimertinib in People with Advanced Non-Small Cell Lung Cancer with an EGFR Mutation
- A Phase I/II Study of MRTX849 in Patients with KRAS G12C-positive Cancers
- A Phase I/IIA Study of CLN-081 in People with Non-Small Cell Lung Cancer
- A Phase II Study of Combination Therapies for Advanced Non-Small Cell Lung Cancer with an EGFR Mutation that Has Grown Despite Osimertinib
- A Phase II Study of DS-7300a in People with Previously Treated Extensive Stage Small Cell Lung Cancer
- A Phase II Study of Osimertinib Alone or with Chemotherapy for Patients with Metastatic EGFR-Mutant Lung Cancers Who Have Detectable Tumor DNA in the Blood After Starting Osimertinib
- A Phase III Study of Osimertinib with or without Bevacizumab as Initial Treatment for Patients with EGFR-Mutant Non-Small Cell Lung Cancer

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Riely’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Gregory J. Riely discloses the following relationships and financial interests:
-
American Association for Cancer Research
Professional Services and Activities (Uncompensated) -
American Society of Clinical Oncology (ASCO)
Professional Services and Activities (Uncompensated) -
Harborside Press LLC
Professional Services and Activities -
MJH Associates
Professional Services and Activities -
Mirati Therapeutics
Professional Services and Activities (Uncompensated) -
National Comprehensive Cancer Network
Professional Services and Activities
-
Pfizer, Inc.
Professional Services and Activities (Uncompensated) -
Phillips Gilmore Oncology Communications, Inc.
Professional Services and Activities -
Research to Practice
Professional Services and Activities -
Takeda Pharmaceuticals
Professional Services and Activities (Uncompensated) -
Triptych Health Partners, LLC
Professional Services and Activities -
Verastem
Professional Services and Activities (Uncompensated)
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].